TRPM1: A Protein Involved in Pain and Inflammation (G4308)

Target Name: TRPM1

NCBI ID: G4308

TRPM1

TRPM1: A Protein Involved in Pain and Inflammation

TRPM1 (Transient receptor potential cation channel subfamily 1) is a protein that is expressed in many different tissues throughout the body. It is involved in the sense of touch and pain, and has been implicated in a number of physiological processes, including the regulation of temperature, inflammation, and pain signaling.

Recent studies have identified TRPM1 as a potential drug target for the treatment of a variety of conditions, including pain, inflammation, and certain neurological disorders. This is because TRPM1 is involved in the signaling of pain and inflammation, and drugs that can inhibit its activity may have therapeutic benefits.

One of the key challenges in studying TRPM1 is its complex structure and the fact that it is expressed in many different tissues. To better understand its role in pain and inflammation, researchers have used a variety of techniques to study its behavior, including biochemical, cellular , and animal models.

One way that researchers have studied TRPM1 is through the use of RNA interference, a technique that allows researchers to knockdown the expression of specific genes in cells. By using this technique, researchers have been able to identify the precise role that TRPM1 plays in pain and inflammation.

Another approach that researchers have used to study TRPM1 is through the use of small molecules, which are drugs that can bind to specific proteins and alter their activity. By using this approach, researchers have been able to identify potential drugs that can inhibit the activity of TRPM1 and improve pain and inflammation in animals.

While these studies are promising, there are still many questions that need to be answered about TRPM1 and its potential as a drug target. For example, it is not yet clear exactly how TRPM1 is involved in pain and inflammation, or what the most effective way to inhibit its activity would be. Additionally, there are concerns that TRPM1 may be involved in other important physiological processes, so it is important to carefully study its role before deciding on it as a drug target.

Despite these challenges, researchers are continuing to study TRPM1 and its potential as a drug target. By the next generation, it is hoped that will be able to provide new insights into the complex role of TRPM1 in pain and inflammation, and may lead to the development of new treatments for a variety of conditions.

Protein Name: Transient Receptor Potential Cation Channel Subfamily M Member 1

Functions: Forms nonselective divalent cation-conducting channels which mediate the influx of Na(2+), Ca(2+), Mg(2+), Mn(2+), Ba(2+), and Ni(2+) into the cytoplasm, leading to membrane depolarization (PubMed:19436059, PubMed:21278253). Impermeable to zinc ions (PubMed:21278253). In addition, forms heteromultimeric ion channels with TRPM3 which are permeable for calcium and zinc ions (PubMed:21278253). Essential for the depolarizing photoresponse of retinal ON bipolar cells. It is part of the GRM6 signaling cascade. May play a role in metastasis suppression (By similarity). May act as a spontaneously active, calcium-permeable plasma membrane channel

The "TRPM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRPM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets